Tranexamic Acid Update in Trauma

Critical Care Clinics

Volumn 33, Issue 1, 2017, Pages 85-99

  Ramirez, Ricardo J ^a   Spinella, Philip C ^a   Bochicchio, Grant V ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antifibrinolytics; Coagulopathy; Hemorrhage; Surgery; Tranexamic acid; Trauma

Indexed keywords

ANTIFIBRINOLYTIC AGENT; TRANEXAMIC ACID;

ACUTE DISEASE; ACUTE TRAUMATIC COAGULOPATHY; ANTICOAGULATION; BLOOD CLOTTING DISORDER; BLOOD TRANSFUSION; CHILD CARE; CHILDHOOD INJURY; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG MECHANISM; DRUG USE; EMERGENCY CARE; FIBRINOLYSIS; HUMAN; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESUSCITATION; REVIEW; SEIZURE; VISCOELASTICITY; HEMORRHAGE; WOUNDS AND INJURIES;

ANTIFIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; TRANEXAMIC ACID; WOUNDS AND INJURIES;

EID: 84997831716     PISSN: 07490704     EISSN: 15578232     Source Type: Journal    
DOI: 10.1016/j.ccc.2016.08.004     Document Type: Review

References (85)

1. 1 Ker, K., Kiriya, J., Perel, P., et al. Avoidable mortality from giving tranexamic acid to bleeding trauma patients: an estimation based on WHO mortality data, a systematic literature review and data from the CRASH-2 trial. BMC Emerg Med, 12, 2012, 3.
2. 2 Injuries and violence: the facts, 2010, World Health Organization, Geneva (Switzerland) Available at: http://www.who.int/violence_injury_prevention/key_facts/en/ Accessed April 28, 2016.
3. 3 Nadler, R., Gendler, S., Benov, A., et al. Tranexamic acid at the point of injury: the Israeli combined civilian and military experience. J Trauma Acute Care Surg 77:3 Suppl 2 (2014), S146–S150.
4. 4 Frith, D., Brohi, K., The acute coagulopathy of trauma shock: clinical relevance. Surgeon 8:3 (2010), 159–163.
5. 5 Eastridge, B.J., Mabry, R.L., Seguin, P., et al. Death on the battlefield (2001-2011): implications for the future of combat casualty care. J Trauma Acute Care Surg 73:6 Suppl 5 (2012), S431–S437.
6. 6 Evans, J.A., van Wessem, K.J., McDougall, D., et al. Epidemiology of traumatic deaths: comprehensive population-based assessment. World J Surg 34:1 (2010), 158–163.
7. 7 Morrison, J.J., Dubose, J.J., Rasmussen, T.E., et al. Military Application of Tranexamic Acid in Trauma Emergency Resuscitation (MATTERs) Study. Arch Surg 147:2 (2012), 113–119.
8. 8 Shakur, H., Roberts, I., Bautista, R., et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet 376:9734 (2010), 23–32.
9. 9 Napolitano, L.M., Cohen, M.J., Cotton, B.A., et al. Tranexamic acid in trauma: how should we use it?. J Trauma Acute Care Surg 74:6 (2013), 1575–1586.
10. 10 Pusateri, A.E., Weiskopf, R.B., Bebarta, V., et al. Tranexamic acid and trauma: current status and knowledge gaps with recommended research priorities. Shock 39:2 (2013), 121–126.
11. 11 Cole, E., Davenport, R., Willett, K., et al. Tranexamic acid use in severely injured civilian patients and the effects on outcomes: a prospective cohort study. Ann Surg 261:2 (2015), 390–394.
12. 12 Brown, J.B., Neal, M.D., Guyette, F.X., et al. Design of the Study of Tranexamic Acid during Air Medical Prehospital Transport (STAAMP) Trial: addressing the knowledge gaps. Prehosp Emerg Care 19:1 (2015), 79–86.
13. 13 Spinella PC, Bochicchio GV. Tranexamic Acid Mechanisms and Pharmacokinetics In Traumatic Injury (TAMPITI Trial). Available at: http://www.tampiti.wustl.edu/. Accessed April 16, 2016.
14. 14 Dewan, Y., Komolafe, E.O., Mejia-Mantilla, J.H., et al. CRASH-3-tranexamic acid for the treatment of significant traumatic brain injury: study protocol for an international randomized, double-blind, placebo-controlled trial. Trials, 13, 2012, 87.
15. 15 Gruen, R.L., Jacobs, I.G., Reade, M.C., Trauma and tranexamic acid. Med J Aust 199:5 (2013), 310–311.
16. 16 Shakur, H., Elbourne, D., Gulmezoglu, M., et al. The WOMAN Trial (World Maternal Antifibrinolytic Trial): tranexamic acid for the treatment of postpartum haemorrhage: an international randomised, double blind placebo controlled trial. Trials, 11, 2010, 40.
17. 17 Roberts, I., Coats, T., Edwards, P., et al. HALT-IT–tranexamic acid for the treatment of gastrointestinal bleeding: study protocol for a randomised controlled trial. Trials, 15, 2014, 450.
18. 18 Binz, S., McCollester, J., Thomas, S., et al. CRASH-2 study of tranexamic acid to treat bleeding in trauma patients: a controversy fueled by science and social media. J Blood Transfus, 2015, 2015, 874920.
19. 19 Tengborn, L., Blomback, M., Berntorp, E., Tranexamic acid–an old drug still going strong and making a revival. Thromb Res 135:2 (2015), 231–242.
20. 20 CYKLOKAPRON- tranexamic acid injection, solution Pharmacia and Upjohn Company. Available at: http://labeling.pfizer.com/ShowLabeling.aspx?id=556. Accessed April 20, 2016.
21. 21 Cap, A.P., Baer, D.G., Orman, J.A., et al. Tranexamic acid for trauma patients: a critical review of the literature. J Trauma 71:Suppl 1 (2011), S9–S14.
22. 22 Abou-Diwan, C., Sniecinski, R.M., Szlam, F., et al. Plasma and cerebral spinal fluid tranexamic acid quantitation in cardiopulmonary bypass patients. J Chromatogr B Analyt Technol Biomed Life Sci 879:7–8 (2011), 553–556.
23. 23 Bernet, F., Carrel, T., Marbet, G., et al. Reduction of blood loss and transfusion requirements after coronary artery bypass grafting: similar efficacy of tranexamic acid and aprotinin in aspirin-treated patients. J Card Surg 14:2 (1999), 92–97.
24. 24 Bokesch, P.M., Szabo, G., Wojdyga, R., et al. A phase 2 prospective, randomized, double-blind trial comparing the effects of tranexamic acid with ecallantide on blood loss from high-risk cardiac surgery with cardiopulmonary bypass (CONSERV-2 Trial). J Thorac Cardiovasc Surg 143:5 (2012), 1022–1029.
25. 25 Couturier, R., Rubatti, M., Credico, C., et al. Continuous or discontinuous tranexamic acid effectively inhibits fibrinolysis in children undergoing cardiac surgery with cardiopulmonary bypass. Blood Coagul Fibrinolysis 25:3 (2014), 259–265.
26. 26 Jimenez, J.J., Iribarren, J.L., Lorente, L., et al. Tranexamic acid attenuates inflammatory response in cardiopulmonary bypass surgery through blockade of fibrinolysis: a case control study followed by a randomized double-blind controlled trial. Crit Care, 11(6), 2007, R117.
27. 27 Kalavrouziotis, D., Voisine, P., Mohammadi, S., et al. High-dose tranexamic acid is an independent predictor of early seizure after cardiopulmonary bypass. Ann Thorac Surg 93:1 (2012), 148–154.
28. 28 Karski, J.M., Teasdale, S.J., Norman, P., et al. Prevention of bleeding after cardiopulmonary bypass with high-dose tranexamic acid: double-blind, randomized clinical trial. J Thorac Cardiovasc Surg 110:3 (1995), 835–842.
29. 29 Royston, D., The current place of aprotinin in the management of bleeding. Anaesthesia 70:Suppl 1 (2015), 46–49 e17.
30. 30 Jennings, J.D., Solarz, M.K., Haydel, C., Application of tranexamic acid in trauma and orthopedic surgery. Orthop Clin North Am 47:1 (2016), 137–143.
31. 31 Tsutsumimoto, T., Shimogata, M., Ohta, H., et al. Tranexamic acid reduces perioperative blood loss in cervical laminoplasty: a prospective randomized study. Spine (Phila Pa 1976) 36:23 (2011), 1913–1918.
32. 32 Sabatini, L., Atzori, F., Revello, S., et al. Intravenous use of tranexamic acid reduces postoperative blood loss in total knee arthroplasty. Arch Orthop Trauma Surg 134:11 (2014), 1609–1614.
33. 33 Gillespie, R., Shishani, Y., Joseph, S., et al. Neer Award 2015: a randomized, prospective evaluation on the effectiveness of tranexamic acid in reducing blood loss after total shoulder arthroplasty. J Shoulder Elbow Surg 24:11 (2015), 1679–1684.
34. 34 Brohi, K., Cohen, M.J., Ganter, M.T., et al. Acute traumatic coagulopathy: initiated by hypoperfusion: modulated through the protein C pathway?. Ann Surg 245:5 (2007), 812–818.
35. 35 Ker, K., Edwards, P., Perel, P., et al. Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis. BMJ, 344, 2012, e3054.
36. 36 Roberts, I., Shakur, H., Afolabi, A., et al. The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet 377:9771 (2011), 1096–1101 1101.e1–2.
37. 37 Roberts, I., Shakur, H., Coats, T., et al. The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients. Health Technol Assess 17:10 (2013), 1–79.
38. 38 Roberts, I., Tranexamic acid in trauma: how should we use it?. J Thromb Haemost 13:Suppl 1 (2015), S195–S199.
39. 39 Harvin, J.A., Peirce, C.A., Mims, M.M., et al. The impact of tranexamic acid on mortality in injured patients with hyperfibrinolysis. J Trauma Acute Care Surg 78:5 (2015), 905–909 [discussion: 909–11].
40. 40 Moore, H.B., Moore, E.E., Gonzalez, E., et al. Hyperfibrinolysis, physiologic fibrinolysis, and fibrinolysis shutdown: the spectrum of postinjury fibrinolysis and relevance to antifibrinolytic therapy. J Trauma Acute Care Surg 77:6 (2014), 811–817 [discussion: 817].
41. 41 Valle, E.J., Allen, C.J., Van Haren, R.M., et al. Do all trauma patients benefit from tranexamic acid?. J Trauma Acute Care Surg 76:6 (2014), 1373–1378.
42. 42 Brohi, K., Singh, J., Heron, M., et al. Acute traumatic coagulopathy. J Trauma 54:6 (2003), 1127–1130.
43. 43 Jenkins, D.H., Rappold, J.F., Badloe, J.F., et al. Trauma hemostasis and oxygenation research position paper on remote damage control resuscitation: definitions, current practice, and knowledge gaps. Shock 41:Suppl 1 (2014), 3–12.
44. 44 Davenport, R.A., Brohi, K., Cause of trauma-induced coagulopathy. Curr Opin Anaesthesiol 29:2 (2016), 212–219.
45. 45 Brohi, K., Cohen, M.J., Ganter, M.T., et al. Acute coagulopathy of trauma: hypoperfusion induces systemic anticoagulation and hyperfibrinolysis. J Trauma 64:5 (2008), 1211–1217 [discussion: 1217].
46. 46 Dirkmann, D., Radu-Berlemann, J., Gorlinger, K., et al. Recombinant tissue-type plasminogen activator-evoked hyperfibrinolysis is enhanced by acidosis and inhibited by hypothermia but still can be blocked by tranexamic acid. J Trauma Acute Care Surg 74:2 (2013), 482–488.
47. 47 Frith, D., Davenport, R., Brohi, K., Acute traumatic coagulopathy. Curr Opin Anaesthesiol 25:2 (2012), 229–234.
48. 48 Raza, I., Davenport, R., Rourke, C., et al. The incidence and magnitude of fibrinolytic activation in trauma patients. J Thromb Haemost 11:2 (2013), 307–314.
49. 49 Moore, H.B., Moore, E.E., Liras, I.N., et al. Acute fibrinolysis shutdown after injury occurs frequently and increases mortality: a multicenter evaluation of 2,540 severely injured patients. J Am Coll Surg 222:4 (2016), 347–355.
50. 50 Moore, E.E., Moore, H.B., Gonzalez, E., et al. Rationale for the selective administration of tranexamic acid to inhibit fibrinolysis in the severely injured patient. Transfusion 56:Suppl 2 (2016), S110–S114.
51. 51 Roberts, I., Fibrinolytic shutdown: fascinating theory but randomized controlled trial data are needed. Transfusion 56:Suppl 2 (2016), S115–S118.
52. 52 Laffey, J.G., Boylan, J.F., Cheng, D.C., The systemic inflammatory response to cardiac surgery: implications for the anesthesiologist. Anesthesiology 97:1 (2002), 215–252.
53. 53 van der Poll, T., Herwald, H., The coagulation system and its function in early immune defense. Thromb Haemost 112:4 (2014), 640–648.
54. 54 Fergusson, D.A., Hebert, P.C., Mazer, C.D., et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 358:22 (2008), 2319–2331.
55. 55 Asehnoune, K., Dehoux, M., Lecon-Malas, V., et al. Differential effects of aprotinin and tranexamic acid on endotoxin desensitization of blood cells induced by circulation through an isolated extracorporeal circuit. J Cardiothorac Vasc Anesth 16:4 (2002), 447–451.
56. 56 Wong, B.I., McLean, R.F., Fremes, S.E., et al. Aprotinin and tranexamic acid for high transfusion risk cardiac surgery. Ann Thorac Surg 69:3 (2000), 808–816.
57. 57 White, N., Bayliss, S., Moore, D., Systematic review of interventions for minimizing perioperative blood transfusion for surgery for craniosynostosis. J Craniofac Surg 26:1 (2015), 26–36.
58. 58 Faraoni, D., Goobie, S.M., The efficacy of antifibrinolytic drugs in children undergoing noncardiac surgery: a systematic review of the literature. Anesth Analg 118:3 (2014), 628–636.
59. 59 Faraoni, D., Willems, A., Melot, C., et al. Efficacy of tranexamic acid in paediatric cardiac surgery: a systematic review and meta-analysis. Eur J Cardiothorac Surg 42:5 (2012), 781–786.
60. 60 Eckert, M.J., Wertin, T.M., Tyner, S.D., et al. Tranexamic acid administration to pediatric trauma patients in a combat setting: the pediatric trauma and tranexamic acid study (PED-TRAX). J Trauma Acute Care Surg 77:6 (2014), 852–858 [discussion: 858].
61. 61 Beno, S., Ackery, A.D., Callum, J., et al. Tranexamic acid in pediatric trauma: why not?. Crit Care, 18(4), 2014, 313.
62. 62 Nishijima, D.K., Monuteaux, M.C., Faraoni, D., et al. Tranexamic acid use in United States Children's Hospitals. J Emerg Med 50:6 (2016), 868–874.e1.
63. 63 Horst, J., Leonard, J.C., Vogel, A., et al. A survey of US and Canadian hospitals' paediatric massive transfusion protocol policies. Transfus Med 26:1 (2016), 49–56.
64. 64 Patregnani, J.T., Borgman, M.A., Maegele, M., et al. Coagulopathy and shock on admission is associated with mortality for children with traumatic injuries at combat support hospitals. Pediatr Crit Care Med 13:3 (2012), 273–277.
65. 65 Baharoglu, M.I., Germans, M.R., Rinkel, G.J., et al. Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev, 8, 2013, Cd001245.
66. 66 Meretoja, A., Churilov, L., Campbell, B.C., et al. The spot sign and tranexamic acid on preventing ICH growth–AUStralasia Trial (STOP-AUST): protocol of a phase II randomized, placebo-controlled, double-blind, multicenter trial. Int J Stroke 9:4 (2014), 519–524.
67. 67 Horrow, J.C., Hlavacek, J., Strong, M.D., et al. Prophylactic tranexamic acid decreases bleeding after cardiac operations. J Thorac Cardiovasc Surg 99:1 (1990), 70–74.
68. 68 Horrow, J.C., Van Riper, D.F., Strong, M.D., et al. The dose-response relationship of tranexamic acid. Anesthesiology 82:2 (1995), 383–392.
69. 69 Mitra, B., Mazur, S., Cameron, P.A., et al. Tranexamic acid for trauma: filling the ‘GAP’ in evidence. Emerg Med Australas 26:2 (2014), 194–197.
70. 70 Farrell, N.M., Wing, H.A., Burke, P.A., et al. Addition of tranexamic acid to a traumatic injury massive transfusion protocol. Am J Health Syst Pharm 72:12 (2015), 1059–1064.
71. 71 Maegele, M., Coagulation factor concentrate-based therapy for remote damage control resuscitation (RDCR): a reasonable alternative?. Transfusion 56:Suppl 2 (2016), S157–S165.
72. 72 Kelly, J.F., Ritenour, A.E., McLaughlin, D.F., et al. Injury severity and causes of death from Operation Iraqi Freedom and Operation Enduring Freedom: 2003-2004 versus 2006. J Trauma 64:Suppl 2 (2008), S21–S26 [discussion: S26–7].
73. 73 Holcomb, J.B., McMullin, N.R., Pearse, L., et al. Causes of death in U.S. Special Operations Forces in the global war on terrorism: 2001-2004. Ann Surg 245:6 (2007), 986–991.
74. 74 Paudyal, P., Smith, J., Robinson, M., et al. Tranexamic acid in major trauma: implementation and evaluation across South West England. Eur J Emerg Med, 2015 [Epub ahead of print].
75. 75 Ausset, S., Glassberg, E., Nadler, R., et al. Tranexamic acid as part of remote damage-control resuscitation in the prehospital setting: a critical appraisal of the medical literature and available alternatives. J Trauma Acute Care Surg 78:6 Suppl 1 (2015), S70–S75.
76. 76 Vu, E.N., Schlamp, R.S., Wand, R.T., et al. Prehospital use of tranexamic acid for hemorrhagic shock in primary and secondary air medical evacuation. Air Med J 32:5 (2013), 289–292.
77. 77 Mrochuk, M., ÓDochartaigh, D., Chang, E., Rural trauma patients cannot wait: tranexamic acid administration by helicopter emergency medical services. Air Med J 34:1 (2015), 37–39.
78. 78 Lipsky, A.M., Abramovich, A., Nadler, R., et al. Tranexamic acid in the prehospital setting: Israel Defense Forces' initial experience. Injury 45:1 (2014), 66–70.
79. 79 Rappold, J.F., Pusateri, A.E., Tranexamic acid in remote damage control resuscitation. Transfusion 53:Suppl 1 (2013), 96S–99S.
80. 80 Gonzalez, E., Moore, E.E., Moore, H.B., et al. Goal-directed hemostatic resuscitation of trauma-induced coagulopathy: a pragmatic randomized clinical trial comparing a viscoelastic assay to conventional coagulation assays. Ann Surg 263:6 (2016), 1051–1059.
81. 81 Kobayashi, L., Costantini, T.W., Coimbra, R., Hypovolemic shock resuscitation. Surg Clin North Am 92:6 (2012), 1403–1423.
82. 82 Maegele, M., Spinella, P.C., Schochl, H., The acute coagulopathy of trauma: mechanisms and tools for risk stratification. Shock 38:5 (2012), 450–458.
83. 83 Lecker, I., Wang, D.S., Romaschin, A.D., et al. Tranexamic acid concentrations associated with human seizures inhibit glycine receptors. J Clin Invest 122:12 (2012), 4654–4666.
84. 84 Hillman, J., Fridriksson, S., Nilsson, O., et al. Immediate administration of tranexamic acid and reduced incidence of early rebleeding after aneurysmal subarachnoid hemorrhage: a prospective randomized study. J Neurosurg 97:4 (2002), 771–778.
85. 85 Prehospital tranexamic acid use for traumatic brain injury. Available at: https://clinicaltrials.gov/ct2/show/NCT01990768. Accessed April 21, 2016.